MLL Antibody (HRX107): sc-53371
- MLL Antibody (HRX107) is a mouse monoclonal mouse IgM, cited in 1 publications, provided at 200 µg/ml
- raised against amino acids 839-854 of MLL of human origin
- recommended for detection of MLL of mouse, rat and human origin by WB and IF
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for MLL Antibody (HRX107). This work is in progress.
MLL Antibody (HRX107) is a mouse monoclonal IgM antibody that detects MLL protein of mouse, rat, and human origin by western blotting (WB) and immunofluorescence (IF). MLL protein, also known as myeloid/lymphoid leukemia protein, plays a crucial role in regulating embryonal and hematopoietic development, making MLL essential for proper cellular differentiation and proliferation. MLL function is particularly significant in acute myeloid leukemia, where MLL gene undergoes translocation with other genes, leading to oncogenic fusion proteins that disrupt normal gene regulation. MLL protein is involved in transcriptional regulation of various target genes, influencing processes such as cell cycle progression and apoptosis. Given MLL′s pivotal role in gene expression and development, MLL is a key focus in cancer research, particularly in understanding mechanisms underlying leukemia. Anti-MLL antibody (HRX107) is an invaluable tool for researchers studying complexities of gene regulation and molecular pathways involved in hematopoietic malignancies.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
MLL Antibody (HRX107) References:
- Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. | Krivtsov, AV., et al. 2006. Nature. 442: 818-22. PMID: 16862118
- MLL-ENL-mediated leukemia initiation at the interface of lymphoid commitment. | Ugale, A., et al. 2017. Oncogene. 36: 3207-3212. PMID: 28068328
- A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. | Krivtsov, AV., et al. 2019. Cancer Cell. 36: 660-673.e11. PMID: 31821784
- MLL-Rearranged Acute Lymphoblastic Leukemia. | El Chaer, F., et al. 2020. Curr Hematol Malig Rep. 15: 83-89. PMID: 32350732
- Polycomb complexes in MLL-AF9-related leukemias. | Sparavier, A. and Di Croce, L. 2022. Curr Opin Genet Dev. 75: 101920. PMID: 35609423
- A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin-MLL Inhibition. | Soto-Feliciano, YM., et al. 2023. Cancer Discov. 13: 146-169. PMID: 36264143
- FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia. | Zhu, XN., et al. 2023. J Hematol Oncol. 16: 9. PMID: 36774506
- Circular RNAs drive oncogenic chromosomal translocations within the MLL recombinome in leukemia. | Conn, VM., et al. 2023. Cancer Cell. 41: 1309-1326.e10. PMID: 37295428
- Epigenetic balance ensures mechanistic control of MLL amplification and rearrangement. | Gray, ZH., et al. 2023. Cell. 186: 4528-4545.e18. PMID: 37788669
- MLL oncoprotein levels influence leukemia lineage identities. | Janssens, DH., et al. 2024. Nat Commun. 15: 9341. PMID: 39472576
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MLL Antibody (HRX107) | sc-53371 | 200 µg/ml | $316.00 |